An Open-label, Randomized, Single-dose, Three-way Crossover Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to 5 mg Mavacamten Intact Capsule in Healthy Participants
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Mavacamten (Primary) ; Mavacamten (Primary) ; Mavacamten (Primary)
- Indications Heart failure; Hypertrophic cardiomyopathy
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 19 Sep 2024 Status changed from recruiting to completed.
- 23 Jan 2024 New trial record
- 19 Jan 2024 Planned initiation date changed from 30 Jan 2024 to 7 Feb 2024.